OXiGENE (OXGN) Leaps on Study Results

OXiGENE Inc (NASDAQ: OXGN) rose 46.3% to 82 cents, as the company reported that results of its Phase 2 study of CA4P in recurrent ovarian cancer has been published in Journal of Clinical Oncology. The study met primary endpoint of improvement. Share volume was 12.8 million, compared to an all-day average of 150,000
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.